AXA S.A. - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 342 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.2%.

Quarter-by-quarter ownership
AXA S.A. ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$974,100
+13.9%
25,500
+7.6%
0.00%0.0%
Q2 2023$854,859
-40.8%
23,700
-37.3%
0.00%
-40.0%
Q1 2023$1,444,537
-28.8%
37,825
+6.0%
0.01%
-28.6%
Q4 2022$2,029,737
-54.7%
35,672
-68.5%
0.01%
-22.2%
Q3 2022$4,481,811
+981.6%
113,344
+989.8%
0.01%
+800.0%
Q1 2022$414,376
-88.8%
10,400
-88.7%
0.00%
-88.9%
Q4 2021$3,687,000
-27.9%
91,700
-27.0%
0.01%
-35.7%
Q3 2021$5,113,000
+36.2%
125,700
+43.0%
0.01%
+16.7%
Q4 2020$3,754,000
+383.8%
87,900
+75.8%
0.01%
+500.0%
Q3 2019$776,000
-94.8%
50,000
-94.3%
0.00%
-93.1%
Q2 2019$14,996,000
+117.5%
872,838
+103.8%
0.03%
+7.4%
Q1 2019$6,894,000
+10.0%
428,2170.0%0.03%0.0%
Q4 2018$6,265,000
-19.5%
428,2170.0%0.03%
-6.9%
Q3 2018$7,781,000
+17.9%
428,217
+9.5%
0.03%
+16.0%
Q2 2018$6,598,000
+763.6%
391,109
+787.7%
0.02%
+733.3%
Q4 2015$764,000
-25.8%
44,060
-42.5%
0.00%
-25.0%
Q3 2015$1,029,000
-3.6%
76,600
-34.6%
0.00%
-20.0%
Q3 2014$1,067,000
-8.4%
117,208
-0.6%
0.01%0.0%
Q2 2014$1,165,000
-25.2%
117,961
-3.9%
0.01%
-28.6%
Q1 2014$1,558,000
-10.7%
122,706
+5.5%
0.01%
-12.5%
Q4 2013$1,744,000
+43.0%
116,317
+5.2%
0.01%
+33.3%
Q3 2013$1,220,000
+74.0%
110,531
+25.2%
0.01%
+50.0%
Q2 2013$701,00088,2760.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders